The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD

Chest

Volumn 115, Issue 4, 1999, Pages 966-971

  Dorinsky, Paul M ^a,c,d   Reisner, Colin ^a   Ferguson, Gary T ^b   Menjoge, Shailendra S ^a   Serby, Charles W ^a   Witek Jr , Theodore J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NONE   (United States)

Author keywords

Albuterol; Bronchodilator; COPD; Ipratropium bromide; Pulmonary function

Indexed keywords

IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG SCREENING; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032960818     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.4.966     Document Type: Article

References (19)

1. 1 Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S120
2. 2 Celli BR. Current thoughts regarding treatment of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80:589-609
3. 3 Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-1022
4. 4 Brand PLP, Quanjer PH, Postma DS, et al. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax 1992; 47:429-436
5. 1. Eur Respir J 1992; 5:975-981
6. 6 Meslier N, Racineux JL, Six P, et al. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. Eur Respir J 1989; 2:497-505
7. 7 Dales RE, Spitzer WO, Tousignant P, et al. Clinical interpretation of airway response to a bronchodilator. Am Rev Respir Dis 1986; 138:317-320
8. 8 Anthonisen NR, Wright EC, and the IPPB trial group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:814-819
9. 9 American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
10. 10 Sclar DA, Legg RF, Skaer TL, et al. Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther 1994; 16: 595-601
11. 11 Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105:1411-1419
12. 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100:40S-48S
13. 13 Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either agent alone in COPD. Chest 1997; 112:1514-1521
14. 14 Morris JF, Koski A, Temple WP, et al. Fifteen-year interval spirometric evaluation of the Oregon predictive equations. Chest 1988; 92:123-127
15. 15 Crapo RO, Hankinson JL, Irving, et al. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
16. 16 Ohrui T, Yanai M, Sekizawa K, et al. Effective site of bronchodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992; 146:88-91
17. 17 Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319: 486-494
18. 18 Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100:11S-18S
19. 19 Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest 1996; 110:62-70